LONG-TERM EFFICACY AND SAFETY OF LANADELUMAB: FINAL RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY

被引：0
|
作者：
Banerji, A.
Hao, J.
Yu, M.
Bernstein, J.
Johnston, D.
Riedl, M.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2020年 / 125卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P150
引用
收藏
页码：S21 / S21
页数：1
相关论文
共 50 条
  • [21] Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study
    Gevaert, Philippe
    Saenz, Rebecca
    Corren, Jonathan
    Han, Joseph K.
    Mullol, Joaquim
    Lee, Stella E.
    Ow, Randall A.
    Zhao, Rui
    Howard, Monet
    Wong, Kit
    Islam, Lutaf
    Ligueros-Saylan, Monica
    Omachi, Theodore A.
    Bachert, Claus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (03) : 957 - +
  • [22] Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: Final results from the Phase 2 open-label extension study
    Ferrante, M.
    Feagan, B. G.
    Panes, J.
    Baert, F.
    Louis, E.
    Dewit, O.
    Kaser, A.
    Duan, W. R.
    Gustafson, D.
    Liao, X.
    Wallace, K.
    Kalabic, J.
    D'Haens, G. R.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S024 - S025
  • [23] Long-term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open-label extension study
    Ito, Tetsuhide
    Fujimori, Nao
    Honma, Yoshitaka
    Kudo, Atsushi
    Hijioka, Susumu
    Katsushima, Shinji
    Kimura, Yasutoshi
    Fukutomi, Akira
    Hisamatsu, Seiichi
    Nakajima, Akihiro
    Shimatsu, Akira
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 (05) : E153 - E161
  • [24] Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
    Jürgen Wollenhaupt
    Eun-Bong Lee
    Jeffrey R. Curtis
    Joel Silverfield
    Ketti Terry
    Koshika Soma
    Chris Mojcik
    Ryan DeMasi
    Sander Strengholt
    Kenneth Kwok
    Irina Lazariciu
    Lisy Wang
    Stanley Cohen
    Arthritis Research & Therapy, 21
  • [25] Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial
    Grossman, J
    Smith, LJ
    Wilson, AM
    Thyrum, PT
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1999, 82 (04) : 361 - 369
  • [26] Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: Interim results of an open-label extension study
    Ng, Yu-Tze
    Conry, Joan
    Paolicchi, Juliann
    Kernitsky, Lydia
    Mitchell, Wendy
    Drummond, Rebecca
    Isojarvi, Jouko
    Lee, Deborah
    Owen, Randall
    EPILEPSY & BEHAVIOR, 2012, 25 (04) : 687 - 694
  • [27] LONG-TERM LANADELUMAB TREATMENT IMPROVES HEALTH-RELATED QUALITY OF LIFE: HELP OPEN-LABEL EXTENSION STUDY INTERIM FINDINGS
    Lumry, W.
    Maurer, M.
    Magerl, M.
    Jain, G.
    Devercelli, G.
    Regnault, A.
    Meunier, J.
    Riedl, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S29 - S29
  • [28] Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
    Tepper, Stewart J.
    Ashina, Messoud
    Reuter, Uwe
    Brandes, Jan Lewis
    Dolezil, David
    Silberstein, Stephen D.
    Winner, Paul
    Zhang, Feng
    Cheng, Sunfa
    Mikol, Daniel D.
    CEPHALALGIA, 2020, 40 (06) : 543 - 553
  • [29] Safety and efficacy of tofacitinib for up to 9.5years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
    Wollenhaupt, Juergen
    Lee, Eun-Bong
    Curtis, Jeffrey R.
    Silverfield, Joel
    Terry, Ketti
    Soma, Koshika
    Mojcik, Chris
    DeMasi, Ryan
    Strengholt, Sander
    Kwok, Kenneth
    Lazariciu, Irina
    Wang, Lisy
    Cohen, Stanley
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [30] Safety of long-term use of linezolid: results of an open-label study
    Vazquez, Jose A.
    Arnold, Anthony C.
    Swanson, Robert N.
    Biswas, Pinaki
    Bassetti, Matteo
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 1347 - 1354
12345